NIHR Oxford Biomedical Research Centre

Enabling translational research through partnership

MENUMENU
  • About
    • About the NIHR Oxford Biomedical Research Centre
    • A Guide to What We Do
    • Activities during COVID-19
    • Strategic Partnership Board
    • Steering Committee
    • Promoting Equality, Diversity and Inclusion in Research
    • Current Vacancies
    • Contact Us
    • Stay in Touch
  • Research
        • OUR 20 RESEARCH THEMES

        • Antimicrobial Resistance and Modernising Microbiology
        • Cardiovascular
        • Clinical Informatics and Big Data
        • Diabetes and Metabolism
        • Gastroenterology and Mucosal Immunity
        • Genomic Medicine
        • Haematology and Stem Cells
        • Imaging
        • Molecular Diagnostics
        • Multi-Modal Cancer Therapies
        • Multi-Morbidity and Long-Term Conditions
        • Musculoskeletal
        • Neurological Conditions
        • Obesity, Diet and Lifestyle
        • Partnerships for Health, Wealth and Innovation
        • Respiratory
        • Stroke and Vascular Dementia
        • Surgical Innovation and Evaluation
        • Technology and Digital Health
        • Vaccines for Emerging and Endemic Diseases
        • Oxford Biomedical Research Centre activities during COVID-19
  • Patient & Public Involvement
    • Getting involved with research
    • Researcher Guidance
    • Post an opportunity for patient and public involvement
  • Training Hub
    • Training Hub Overview
    • Clinical Academic Pathway
    • Internships
    • Preparatory Research Fellowships
    • Senior Research Fellowships
    • Research Training Bursaries
    • Doctoral Awards
    • Post-Doctoral Awards
    • Other funding
    • Leadership Training
    • Useful Links
    • Training and Education Resources
    • Upcoming Training Events & Courses
  • Industry
    • Collaborate with Oxford BRC
    • What Can We Do For Your Organisation?
    • Who Do We Work With?
    • IP and Licensing
    • Contacts for Industry
  • Videos
  • News
  • Events

News

You are here: Home > COVID-19 > Managing clinical trials in a pandemic: interview with Prof Duncan Richards

Managing clinical trials in a pandemic: interview with Prof Duncan Richards

5 May 2020 · Listed under COVID-19

Duncan Richards

Professor Duncan Richards, who is Director of the Oxford Clinical Trials Research Unit (OCTRU) as well as the NIHR Oxford Biomedical Research Centre’s Musculoskeletal Co-theme Lead, is at the forefront of Oxford’s strategy on clinical trials for COVID-19. In this interview with the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), he discusses how Oxford is responding to the pandemic and the challenges of running clinical trials in this environment.  

What has been your role in the Oxford response to the COVID-19 pandemic?

This pandemic is characterised for me by two groups. There are those who are on the front line, treating patients, often rushed off their feet dealing with immediate needs of patients and logistic matters.

In a place like Oxford you also have a huge number of ‘armchair generals’ who are isolated at home and really want to make a contribution. They have the opportunity to devour the emerging literature and to formulate great ideas. We need both these groups to work together to deliver for patients.

I am leading the COVID Clinical Trial Planning Group, which works at this interface. We have a real multidisciplinary group encompassing immunologists, respiratory, infectious disease, intensive care, emergency medicine and gerontology. The national framework sets the overall agenda but it is vital to have a local plan to be able to deliver.

A great strength of our group is that over 50% are also working on the front line. Not necessarily all day every day, but they are seeing patients on a regular basis. For me, it has been a critical insight into how you conduct research in a pandemic environment.

What has been the focus for the group since it formed to conduct clinical trials?

What our planning group has been really focused on is a strategy for our clinical studies. We must have reviewed 30 plus proposals for clinical trials, but all too often they’re all looking to recruit the same patients, and that’s not possible. So, we’ve been doing two things. One is we’ve been working with senior leadership in the Medical Sciences Division to identify and prioritise those interventions that we think are most promising.

The other thing is working with the people proposing these studies to come up with constructive advice on where this intervention might fit into the care pathway of patients. For example, you have prophylaxis of healthcare workers, you have studies in general practice, studies in the emergency department, then on patients who are admitted to hospital, and studies that are done in the intensive care unit.

Now, in each of these domains you can’t have 13 studies all trying to recruit the same patient, so you have to prioritise. A specific example is the ATOMIC 2 study. ATOMIC 1 was an inpatient study that would have directly competed with a national platform study called RECOVERY. So, we worked with the team to refocus that study, and it’s now going to be focused on people who have COVID-19, attend the emergency department, but don’t need to be admitted to hospital. We’re going to see whether the treatment in that case can stop them needing to be admitted to hospital.

There are some good proposals that are just misplaced and we’re really trying to help people with that rather than just act as a prioritisation committee. I think the insight that we bring comes not only from having clever scientists and immunologists, and people who are working on the front line, but also from a range of disciplines. It’s not a pressure group for a particular organ specialty, which I think is different.

In the clinical trials to date, what are the treatments being focused on in relation to COVID-19?

Oxford is phenomenally prominent in this space.

  • The health care practitioner prophylaxis study, COPCOV, is a study led by Nick White in in Thailand, who’s a Nuffield Department of Medicine (NDM) professor. This is a very large international trial that’s being supported by the Diabetes Trial Unit, and there will be local enrolment.
  • The National GP platform, called PRINCIPLE, is being run by Richard Hobbs and Chris Butler in Primary Care, and supported by their trials unit. So far 200 patients have been recruited.
  • The Emergency Department study, ATOMIC 2, is being led out of Respiratory Medicine, and the Oxford Clinical Trials Research Unit (OCTRU) at NDORMS is supporting that study which is awaiting approval from authorities.
  • RECOVERY is the big national platform for inpatients which has over 8000 patients recruited. It is being run by the Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU) and being led by Peter Horby and Martin Landray.
  • The intensive care platform study is called REMAP-CAP, which is actually an international collaboration of ICU units that Oxford is participating in.

So actually, Oxford University as a whole is making an enormous contribution, beyond all the vaccine work as well, which is very prominent.

What are the challenges of conducting trials during these unprecedented times?

I think there are a few principles here, which is that you have to keep things as simple and as consistent as you can in these clinical trials because it’s a rushed and constrained environment for clinical research.

My planning group is connected directly with a prioritisation group chaired by Helen McShane and Keith Channon, which includes the leadership of Clinical Trials & Research Governance (CTRG), so that we are all focused on using our infrastructure resources to support those things that are prioritised and are the most encouraging. And the Medicines and Healthcare Products Regulatory Agency (MHRA), the Health Research Authority (HRA) and the Ethics Framework are also working very, very fast in the environment.

But we’re also doing what we can locally to fast track things. The setup time has been really substantially reduced and is moving very, very fast at the moment. As an example, for ATOMIC 2, OCTRU has done in a fortnight what might normally take a couple of months.

Also, how long the trials take to run is an uncertain picture because, whilst there are lots of patients at the moment, by the time you’re up and running are they going to still be there?

What is your personal view of the Oxford response?

In an emergency, you need coordination. And what Oxford has done is really get behind nationally prioritised work, but also that we’ve tried to organise ourselves locally. But that organisation is not just academics sitting in their living rooms at home, but groups who are working together across disciplines. Oxford is therefore making a very big contribution.

← Oxford COVID-19 vaccine begins human trial stage
BRC theme lead to study ‘remote-by-default’ care in COVID-19 pandemic →

News

  • Lymph nodes reveal more about mechanisms of autoimmunity 14 June 2022
  • Conference aims to forge collaborations to tackle dementia 9 June 2022
  • Lung function device wins top chemistry Prize 8 June 2022
See full news archive

News Categories

Month Archives

Subscribe to the Oxford BRC Newsletter

Keep informed about the work of the Oxford BRC by subscribing to our Mailchimp e-newsletter. It is produced several times a year and delivers news and information about upcoming events straight to your inbox.

Subscribe Now

Oxford BRC on Social Media

  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

Feedback

We’d love to hear your feedback. Please contact us at obrcenquiries@ouh.nhs.uk

  • Sitemap
  • Data Control and Privacy
  • Accessibility
  • Our Partners
  • Disclaimer
  • Contact

Copyright © 2022 NIHR Oxford Biomedical Research Centre